Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI response claim is directly supported by the provided FDA label excerpts under the boxed-warning topics 5.1–5.5, with each component (serious infections, mortality, malignancy, MACE, thrombosis) mapped to the corresponding label section and no contradictions identified.
Category Scores
Accurate Statements
OPZELURA is associated with serious infections.
Supported by label section 5.1 Serious Infections.
OPZELURA is associated with increased mortality.
Supported by label section 5.2 Mortality.
OPZELURA is associated with malignancy.
Supported by label section 5.3 Malignancy and Lymphoproliferative Disorders.
OPZELURA is associated with MACE.
Supported by label section 5.4 Major Adverse Cardiovascular Events (MACE).
OPZELURA is associated with thrombosis.
Supported by label section 5.5 Thrombosis.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluated statement is a high-level safety-risk association and is supported by the label’s boxed-warning topics; no unsafe or unsubstantiated specifics were claimed.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement